Cytogen (Korea) Performance
| 217330 Stock | KRW 4,545 160.00 3.65% |
The firm shows a Beta (market volatility) of -0.0432, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cytogen are expected to decrease at a much lower rate. During the bear market, Cytogen is likely to outperform the market. At this point, Cytogen has a negative expected return of -0.77%. Please make sure to confirm Cytogen's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Cytogen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cytogen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | -5.6 B |
Cytogen |
Cytogen Relative Risk vs. Return Landscape
If you would invest 811,000 in Cytogen on November 3, 2024 and sell it today you would lose (356,500) from holding Cytogen or give up 43.96% of portfolio value over 90 days. Cytogen is generating negative expected returns and assumes 6.5544% volatility on return distribution over the 90 days horizon. Simply put, 58% of stocks are less volatile than Cytogen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cytogen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytogen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytogen, and traders can use it to determine the average amount a Cytogen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1179
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 217330 |
Estimated Market Risk
| 6.55 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.77 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cytogen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytogen by adding Cytogen to a well-diversified portfolio.
Cytogen Fundamentals Growth
Cytogen Stock prices reflect investors' perceptions of the future prospects and financial health of Cytogen, and Cytogen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytogen Stock performance.
| Return On Equity | -96.72 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (9.92) % | |||
| Current Valuation | 324.23 B | |||
| Shares Outstanding | 5.63 M | |||
| Price To Sales | 487.61 X | |||
| Revenue | 347.85 M | |||
| EBITDA | (5.87 B) | |||
| Cash And Equivalents | 30.29 B | |||
| Total Debt | 20.9 B | |||
| Debt To Equity | 0.33 % | |||
| Cash Flow From Operations | (5.23 B) | |||
| Total Asset | 55.53 B | |||
About Cytogen Performance
By analyzing Cytogen's fundamental ratios, stakeholders can gain valuable insights into Cytogen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cytogen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cytogen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cytogen, Inc., a biotechnology company, develops and sells CTC enrichment and downstream systems to treat cancer in South Korea. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea. Cytogen is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Cytogen performance evaluation
Checking the ongoing alerts about Cytogen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytogen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytogen generated a negative expected return over the last 90 days | |
| Cytogen has high historical volatility and very poor performance | |
| The company reported the revenue of 347.85 M. Net Loss for the year was (10.87 B) with loss before overhead, payroll, taxes, and interest of (129.63 M). | |
| Cytogen has accumulated about 30.29 B in cash with (5.23 B) of positive cash flow from operations. | |
| Roughly 39.0% of the company shares are owned by insiders or employees |
- Analyzing Cytogen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytogen's stock is overvalued or undervalued compared to its peers.
- Examining Cytogen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytogen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytogen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytogen's stock. These opinions can provide insight into Cytogen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cytogen Stock analysis
When running Cytogen's price analysis, check to measure Cytogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytogen is operating at the current time. Most of Cytogen's value examination focuses on studying past and present price action to predict the probability of Cytogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytogen's price. Additionally, you may evaluate how the addition of Cytogen to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |